Turning Point Brands (TPB) drew fresh attention after its first quarter results underscored progress in the Modern Oral nicotine pouch segment, with management emphasizing investment and expansion aimed at capturing a larger share of this category by 2030.

Despite the focus on Modern Oral growth, the stock has lost momentum this year, with the share price down 21.49% year to date to US$86.55. At the same time, the 1 year total shareholder return of 14.04% and the very large 3 year total shareholder return of about 3x suggest longer term holders have still seen substantial gains.

If this shift in sentiment has you thinking about where else capital could work, it may be a good time to broaden your search and uncover 20 top founder-led companies

With TPB down this year but showing strong multi year returns and trading at a large discount to the US$130 analyst price target, you need to ask whether there is still upside potential or if growth is already fully reflected in the current share price.

Most Popular Narrative: 33.4% Undervalued

Turning Point Brands' most followed narrative pegs fair value at $130, well above the last close at $86.55. This frames a clear valuation gap for investors to test against their own assumptions.

The company's ability to grow its premium brands in high-margin niches (e.g., Stoker's MST and Zig-Zag) while maintaining strong customer loyalty and executing pricing actions, even as legacy segments decline, underpins stable or improving net margins and cash generation through industry transitions.

Curious how this premium brand focus backs up a higher fair value? The narrative emphasizes rapid top line expansion, higher margins and a richer future earnings multiple. The exact mix of those moving parts is where the story becomes more detailed.

Result: Fair Value of $130 (UNDERVALUED)

However, you still need to weigh the heavy reliance on Modern Oral nicotine pouches, as well as the risk of tighter regulation or aggressive price competition upsetting that valuation story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: DCF Sends a Different Signal

There is a sharp contrast between the US$130 fair value in the popular narrative and the output of the SWS DCF model. On that measure, TPB's estimated future cash flow value is US$39.79, so at US$86.55 the stock screens as expensive rather than undervalued. This raises the question of which set of assumptions you find more realistic.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Turning Point Brands for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution feels familiar, do not wait on the sidelines. Instead, test the story against the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If TPB is already on your radar, do not stop there. Cast the net wider so your capital is not missing out on other compelling setups.

• Target steadier compounding potential by scanning 61 resilient stocks with low risk scores that may suit investors who want calmer portfolios without stepping away from the market.
• Hunt for pricing gaps with the 49 high quality undervalued stocks that highlights companies combining quality fundamentals with what could be appealing entry points.
• Spot future standouts early using the screener containing 21 high quality undiscovered gems and see which under the radar stocks currently pair solid numbers with limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.